Skip to main content
Top
Published in: Diabetologia 12/2006

01-12-2006 | Article

Common variants in HNF-1 α and risk of type 2 diabetes

Authors: J. Holmkvist, C. Cervin, V. Lyssenko, W. Winckler, D. Anevski, C. Cilio, P. Almgren, G. Berglund, P. Nilsson, T. Tuomi, C. M. Lindgren, D. Altshuler, L. Groop

Published in: Diabetologia | Issue 12/2006

Login to get access

Abstract

Aims/hypothesis

Mutations in the hepatocyte nuclear factor 1-α gene (HNF-1α, now known as the transcription factor 1 gene [TCF1]) cause the most common monogenic form of diabetes, MODY3, but it is not known if common variants in HNF-1a are associated with decreased transcriptional activity or phenotypes related to type 2 diabetes, or whether they predict future type 2 diabetes.

Subjects and methods

We studied the effect of four common polymorphisms (rs1920792, I27L, A98V and S487N) in and upstream of the HNF-1α gene on transcriptional activity in vitro, and their possible association with type 2 diabetes and insulin secretion in vivo.

Results

Certain combinations of the I27L and A98V polymorphisms in the HNF-1α gene showed decreased transcriptional activity on the target promoters glucose transporter 2 (now known as solute carrier family 2 [facilitated glucose transporter], member 2) and albumin in both HeLa and INS-1 cells. In vivo, these polymorphisms were associated with a modest but significant impairment in insulin secretion in response to oral glucose. Insulin secretion deteriorated over time in individuals carrying the V allele of the A98V polymorphism (n = 2,293; p = 0.003). In a new case–control (n = 1,511 and n = 2,225 respectively) data set, the I27L polymorphism was associated with increased risk of type 2 diabetes, odds ratio (OR) = 1.5 (p = 0.002; multiple logistic regression), particularly in elderly (age > 60 years) and overweight (BMI > 25 kg/m2) patients (OR = 2.3, p = 0.002).

Conclusions/interpretation

This study provides in vitro and in vivo evidence that common variants in the MODY3 gene, HNF-1α, influence transcriptional activity and insulin secretion in vivo. These variants are associated with a modestly increased risk of late-onset type 2 diabetes in subsets of elderly overweight individuals.
Appendix
Available only for authorised users
Literature
1.
go back to reference Zimmet P, Alberti KGMM, Shaw J (2001) Global and societal implications of the diabetes epidemic. Nature 414:782–787PubMedCrossRef Zimmet P, Alberti KGMM, Shaw J (2001) Global and societal implications of the diabetes epidemic. Nature 414:782–787PubMedCrossRef
2.
go back to reference Gloyn AL, Weedon MN, Owen KR et al (2003) Large-scale association studies of variants in genes encoding the pancreatic beta-cell KATP channel subunits Kir6.2 (KCNJ11) and SUR1 (ABCC8) confirm that the KCNJ11 E23K variant is associated with type 2 diabetes. Diabetes 52:568–572PubMed Gloyn AL, Weedon MN, Owen KR et al (2003) Large-scale association studies of variants in genes encoding the pancreatic beta-cell KATP channel subunits Kir6.2 (KCNJ11) and SUR1 (ABCC8) confirm that the KCNJ11 E23K variant is associated with type 2 diabetes. Diabetes 52:568–572PubMed
3.
go back to reference Altshuler D, Hirschhorn JN, Klannemark M et al (2000) The common PPARgamma Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes. Nat Genet 26:76–80PubMedCrossRef Altshuler D, Hirschhorn JN, Klannemark M et al (2000) The common PPARgamma Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes. Nat Genet 26:76–80PubMedCrossRef
4.
go back to reference Mahtani MM, Widen E, Lehto M et al (1996) Mapping of a gene for type 2 diabetes associated with an insulin secretion defect by a genome scan in Finnish families. Nat Genet 14:90–94PubMedCrossRef Mahtani MM, Widen E, Lehto M et al (1996) Mapping of a gene for type 2 diabetes associated with an insulin secretion defect by a genome scan in Finnish families. Nat Genet 14:90–94PubMedCrossRef
5.
go back to reference Lindgren CM, Mahtani MM, Widen E et al (2002) Genomewide search for type 2 diabetes mellitus susceptibility loci in Finnish families: the Botnia study. Am J Hum Genet 70:509–516PubMedCrossRef Lindgren CM, Mahtani MM, Widen E et al (2002) Genomewide search for type 2 diabetes mellitus susceptibility loci in Finnish families: the Botnia study. Am J Hum Genet 70:509–516PubMedCrossRef
6.
go back to reference Ehm GM, Karnoub MC, Sakul H et al, the American Diabetes Association GENNID Study Group (2000) Genomewide search for type 2 diabetes susceptibility genes in four American populations. Am J Hum Genet 66:1871–1881PubMedCrossRef Ehm GM, Karnoub MC, Sakul H et al, the American Diabetes Association GENNID Study Group (2000) Genomewide search for type 2 diabetes susceptibility genes in four American populations. Am J Hum Genet 66:1871–1881PubMedCrossRef
7.
go back to reference Bowden DW, Sale M, Howard TD et al (1997) Linkage of genetic markers on human chromosomes 20 and 12 to NIDDM in Caucasian sib pairs with a history of diabetic nephropathy. Diabetes 46:882–886PubMed Bowden DW, Sale M, Howard TD et al (1997) Linkage of genetic markers on human chromosomes 20 and 12 to NIDDM in Caucasian sib pairs with a history of diabetic nephropathy. Diabetes 46:882–886PubMed
8.
go back to reference Shaw JT, Lovelock PK, Kesting JB et al (1998) Novel susceptibility gene for late-onset NIDDM is localized to human chromosome 12q. Diabetes 47:1793–1796PubMed Shaw JT, Lovelock PK, Kesting JB et al (1998) Novel susceptibility gene for late-onset NIDDM is localized to human chromosome 12q. Diabetes 47:1793–1796PubMed
9.
go back to reference Wiltshire S, Frayling TM, Groves CJ et al (2004) Evidence from a large UK family collection that genes influencing age of onset of type 2 diabetes map to chromosome 12p and to the MODY3/NIDDM2 locus on 12q24. Diabetes 53:855–860PubMed Wiltshire S, Frayling TM, Groves CJ et al (2004) Evidence from a large UK family collection that genes influencing age of onset of type 2 diabetes map to chromosome 12p and to the MODY3/NIDDM2 locus on 12q24. Diabetes 53:855–860PubMed
10.
go back to reference Reynisdottir I, Thorleifsson G, Benediktsson R et al (2003) Localization of a susceptibility gene for type 2 diabetes to chromosome 5q34–q35.2. Am J Hum Genet 73:323–335PubMedCrossRef Reynisdottir I, Thorleifsson G, Benediktsson R et al (2003) Localization of a susceptibility gene for type 2 diabetes to chromosome 5q34–q35.2. Am J Hum Genet 73:323–335PubMedCrossRef
11.
go back to reference Hegele RA, Cao H, Harris SB, Hanley AJG, Zinman B (1999) The hepatic nuclear factor-1{alpha} G319S variant is associated with early-onset type 2 diabetes in Canadian Oji-Cree. J Clin Endocrinol Metab 84:1077–1082PubMedCrossRef Hegele RA, Cao H, Harris SB, Hanley AJG, Zinman B (1999) The hepatic nuclear factor-1{alpha} G319S variant is associated with early-onset type 2 diabetes in Canadian Oji-Cree. J Clin Endocrinol Metab 84:1077–1082PubMedCrossRef
12.
go back to reference Urhammer S, Fridberg M, Hansen T et al (1997) A prevalent amino acid polymorphism at codon 98 in the hepatocyte nuclear factor-1alpha gene is associated with reduced serum C-peptide and insulin responses to an oral glucose challenge. Diabetes 46:912–916PubMed Urhammer S, Fridberg M, Hansen T et al (1997) A prevalent amino acid polymorphism at codon 98 in the hepatocyte nuclear factor-1alpha gene is associated with reduced serum C-peptide and insulin responses to an oral glucose challenge. Diabetes 46:912–916PubMed
13.
go back to reference Chiu KC, Chuang L-M, Chu A, Wang M (2003) Transcription factor 1 and beta-cell function in glucose-tolerant subjects. Diabet Med 20:225–230PubMedCrossRef Chiu KC, Chuang L-M, Chu A, Wang M (2003) Transcription factor 1 and beta-cell function in glucose-tolerant subjects. Diabet Med 20:225–230PubMedCrossRef
14.
go back to reference Winckler W, Burtt NP, Holmkvist J et al (2005) Association of common variation in the HNF1{alpha} gene region with risk of type 2 diabetes. Diabetes 54:2336–2342PubMed Winckler W, Burtt NP, Holmkvist J et al (2005) Association of common variation in the HNF1{alpha} gene region with risk of type 2 diabetes. Diabetes 54:2336–2342PubMed
15.
go back to reference Weedon MN, Owen KR, Shields B et al (2005) A large-scale association analysis of common variation of the HNF1{alpha} gene with type 2 diabetes in the UK Caucasian population. Diabetes 54:2487–2491PubMed Weedon MN, Owen KR, Shields B et al (2005) A large-scale association analysis of common variation of the HNF1{alpha} gene with type 2 diabetes in the UK Caucasian population. Diabetes 54:2487–2491PubMed
16.
go back to reference Tripathy D, Carlsson Ã-L, Lehto M, Isomaa B, Tuomi T, Groop L (2000) Insulin secretion and insulin sensitivity in diabetic subgroups: studies in the prediabetic and diabetic state. Diabetologia 43:1476–1483PubMedCrossRef Tripathy D, Carlsson Ã-L, Lehto M, Isomaa B, Tuomi T, Groop L (2000) Insulin secretion and insulin sensitivity in diabetic subgroups: studies in the prediabetic and diabetic state. Diabetologia 43:1476–1483PubMedCrossRef
17.
go back to reference Bjorkhaug L, Ye H, Horikawa Y, Sovik O, Molven A, Njolstad PR (2000) MODY associated with two novel hepatocyte nuclear factor-1[alpha] loss-of-function mutations (P112L and Q466X). Biochem Biophys Res Commun 279:792–798PubMedCrossRef Bjorkhaug L, Ye H, Horikawa Y, Sovik O, Molven A, Njolstad PR (2000) MODY associated with two novel hepatocyte nuclear factor-1[alpha] loss-of-function mutations (P112L and Q466X). Biochem Biophys Res Commun 279:792–798PubMedCrossRef
18.
go back to reference Vaxillaire M, Abderrahmani A, Boutin P et al (1999) Anatomy of a homeoprotein revealed by the analysis of human MODY3 mutations. J Biol Chem 274:35639–35646PubMedCrossRef Vaxillaire M, Abderrahmani A, Boutin P et al (1999) Anatomy of a homeoprotein revealed by the analysis of human MODY3 mutations. J Biol Chem 274:35639–35646PubMedCrossRef
19.
go back to reference Lindholm E, Agardh E, Tuomi T, Groop L, Agardh CD (2001) Classifying diabetes according to the new WHO clinical stages. Eur J Epidemiol 17:983–989PubMedCrossRef Lindholm E, Agardh E, Tuomi T, Groop L, Agardh CD (2001) Classifying diabetes according to the new WHO clinical stages. Eur J Epidemiol 17:983–989PubMedCrossRef
20.
go back to reference Alberti KG, Zimmet PZ (1998) Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 15:539–553PubMedCrossRef Alberti KG, Zimmet PZ (1998) Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 15:539–553PubMedCrossRef
21.
go back to reference Groop L, Forsblom C, Lehtovirta M et al (1996) Metabolic consequences of a family history of NIDDM (the Botnia study): evidence for sex-specific parental effects. Diabetes 45:1585–1593PubMed Groop L, Forsblom C, Lehtovirta M et al (1996) Metabolic consequences of a family history of NIDDM (the Botnia study): evidence for sex-specific parental effects. Diabetes 45:1585–1593PubMed
22.
go back to reference Berglund G, Nilsson P, Eriksson K-F et al (2000) Long-term outcome of the Malmö Preventive Project: mortality and cardiovascular morbidity. J Intern Med 247:19–29PubMedCrossRef Berglund G, Nilsson P, Eriksson K-F et al (2000) Long-term outcome of the Malmö Preventive Project: mortality and cardiovascular morbidity. J Intern Med 247:19–29PubMedCrossRef
23.
go back to reference Lyssenko V, Almgren P, Anevski D et al (2005) Predictors of and longitudinal changes in insulin sensitivity and secretion preceding onset of type 2 diabetes. Diabetes 54:166–174PubMed Lyssenko V, Almgren P, Anevski D et al (2005) Predictors of and longitudinal changes in insulin sensitivity and secretion preceding onset of type 2 diabetes. Diabetes 54:166–174PubMed
24.
go back to reference Tripathy D, Eriksson KF, Orho-Melander M, Fredriksson J, Ahlqvist G, Groop L (2004) Parallel manifestation of insulin resistance and beta cell decompensation is compatible with a common defect in Type 2 diabetes. Diabetologia 47:782–793PubMedCrossRef Tripathy D, Eriksson KF, Orho-Melander M, Fredriksson J, Ahlqvist G, Groop L (2004) Parallel manifestation of insulin resistance and beta cell decompensation is compatible with a common defect in Type 2 diabetes. Diabetologia 47:782–793PubMedCrossRef
25.
go back to reference Hoogendoorn B, Coleman SL, Guy CA et al (2003) Functional analysis of human promoter polymorphisms. Hum Mol Genet 12:2249–2254PubMedCrossRef Hoogendoorn B, Coleman SL, Guy CA et al (2003) Functional analysis of human promoter polymorphisms. Hum Mol Genet 12:2249–2254PubMedCrossRef
26.
go back to reference Purcell S, Cherny SS, Sham PC (2003) Genetic power calculator: design of linkage and association genetic mapping studies of complex traits. Bioinformatics 19:149–150PubMedCrossRef Purcell S, Cherny SS, Sham PC (2003) Genetic power calculator: design of linkage and association genetic mapping studies of complex traits. Bioinformatics 19:149–150PubMedCrossRef
27.
go back to reference Liang K, Zeger S (1986) Longitudinal data analysis using generalized linear models. Biometrika 73:13–22CrossRef Liang K, Zeger S (1986) Longitudinal data analysis using generalized linear models. Biometrika 73:13–22CrossRef
28.
go back to reference Liang K, Zeger S (1993) Regression analysis for correlated data. Annu Rev Public Health 4:43–68CrossRef Liang K, Zeger S (1993) Regression analysis for correlated data. Annu Rev Public Health 4:43–68CrossRef
29.
go back to reference Lyssenko V, Almgren P, Anevski D et al (2005) Genetic prediction of future type 2 diabetes. PLoS Medicine 12:1299–1308 Lyssenko V, Almgren P, Anevski D et al (2005) Genetic prediction of future type 2 diabetes. PLoS Medicine 12:1299–1308
30.
go back to reference Eriksson K, Lindgarde F (1990) Impaired glucose tolerance in a middle-aged male urban population: a new approach for identifying high-risk cases. Diabetologia 33:526–531PubMedCrossRef Eriksson K, Lindgarde F (1990) Impaired glucose tolerance in a middle-aged male urban population: a new approach for identifying high-risk cases. Diabetologia 33:526–531PubMedCrossRef
31.
go back to reference Eriksson K, Lindegarde F (1991) Prevention of type 2 (non-insulin-dependent) diabetes mellitus by diet and physical exercise. The 6-year Malmö feasibility study. Diabetiologia 34:891–898CrossRef Eriksson K, Lindegarde F (1991) Prevention of type 2 (non-insulin-dependent) diabetes mellitus by diet and physical exercise. The 6-year Malmö feasibility study. Diabetiologia 34:891–898CrossRef
32.
go back to reference Barrett JC, Fry B, Maller J, Daly MJ (2005) Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 21:263–265PubMedCrossRef Barrett JC, Fry B, Maller J, Daly MJ (2005) Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 21:263–265PubMedCrossRef
33.
go back to reference Gabriel SB, Schaffner SF, Nguyen H et al (2002) The structure of haplotype blocks in the human genome. Science 296:2225–2229PubMedCrossRef Gabriel SB, Schaffner SF, Nguyen H et al (2002) The structure of haplotype blocks in the human genome. Science 296:2225–2229PubMedCrossRef
34.
go back to reference Cervin C, Orho-Melander M, Ridderstrale M et al (2002) Characterization of a naturally occurring mutation (L107I) in the HNF1 alpha (MODY3) gene. Diabetologia 45:1703–1708PubMedCrossRef Cervin C, Orho-Melander M, Ridderstrale M et al (2002) Characterization of a naturally occurring mutation (L107I) in the HNF1 alpha (MODY3) gene. Diabetologia 45:1703–1708PubMedCrossRef
35.
go back to reference Urhammer SA, Moller AM, Nyholm B et al (1998) The effect of two frequent amino acid variants of the hepatocyte nuclear factor-1{alpha} gene on estimates of the pancreatic {beta}-cell function in Caucasian glucose-tolerant first-degree relatives of type 2 diabetic patients. J Clin Endocrinol Metab 83:3992–3995PubMedCrossRef Urhammer SA, Moller AM, Nyholm B et al (1998) The effect of two frequent amino acid variants of the hepatocyte nuclear factor-1{alpha} gene on estimates of the pancreatic {beta}-cell function in Caucasian glucose-tolerant first-degree relatives of type 2 diabetic patients. J Clin Endocrinol Metab 83:3992–3995PubMedCrossRef
36.
go back to reference Chiu KC, Chuang L-M, Ryu JM, Tsai GP, Saad MF (2000) The I27L amino acid polymorphism of hepatic nuclear factor-1{alpha} is associated with insulin resistance. J Clin Endocrinol Metab 85:2178–2183PubMedCrossRef Chiu KC, Chuang L-M, Ryu JM, Tsai GP, Saad MF (2000) The I27L amino acid polymorphism of hepatic nuclear factor-1{alpha} is associated with insulin resistance. J Clin Endocrinol Metab 85:2178–2183PubMedCrossRef
37.
go back to reference Pontoglio M, Sreenan S, Roe M et al (1998) Defective insulin secretion in hepatocyte nuclear factor 1alpha-deficient mice. J Clin Invest 101:2215–2222PubMedCrossRef Pontoglio M, Sreenan S, Roe M et al (1998) Defective insulin secretion in hepatocyte nuclear factor 1alpha-deficient mice. J Clin Invest 101:2215–2222PubMedCrossRef
38.
go back to reference Stride A, Ellard S, Clark P et al (2005) {beta}-Cell dysfunction, insulin sensitivity, and glycosuria precede diabetes in hepatocyte nuclear factor-1{alpha} mutation carriers. Diabetes Care 28:1751–1756PubMed Stride A, Ellard S, Clark P et al (2005) {beta}-Cell dysfunction, insulin sensitivity, and glycosuria precede diabetes in hepatocyte nuclear factor-1{alpha} mutation carriers. Diabetes Care 28:1751–1756PubMed
Metadata
Title
Common variants in HNF-1 α and risk of type 2 diabetes
Authors
J. Holmkvist
C. Cervin
V. Lyssenko
W. Winckler
D. Anevski
C. Cilio
P. Almgren
G. Berglund
P. Nilsson
T. Tuomi
C. M. Lindgren
D. Altshuler
L. Groop
Publication date
01-12-2006
Publisher
Springer-Verlag
Published in
Diabetologia / Issue 12/2006
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-006-0450-x

Other articles of this Issue 12/2006

Diabetologia 12/2006 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.